Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Clin Cancer Res. 2019 Sep 12;25(23):7089–7097. doi: 10.1158/1078-0432.CCR-19-2004

Fig. 3. Survival of patients with non-V600 BRAF alterations.

Fig. 3.

(A) PFS in a total of 25 patients treated with anti-EGFR antibody at the third- or later-line, or (B) stratified by BRAF mutation class. (C) Measurements of cell tumor DNA before and during treatment with panitumumab and irinotecan. Numbers for highest allelic fraction correspond to BRAF D594G mutant allelic fraction detected in blood.